文献速递咽喉与嗓音头颈外科

声带白斑的连续门诊激光治疗:疾病控制与嗓音结局

Serial in-office laser treatment of vocal fold leukoplakia: Disease control and voice outcomes.
PubMed 文献 · Laryngoscope · 2017-01-13

回顾性分析2008—2015年46例接受门诊KTP或PDL激光治疗的声带白斑患者,末次治疗后中位随访19.6个月。总体疾病消退中位77.1%(P<0.001),19例(41.3%)无病变,2例(4.3%)进展为浸润癌,VHI-10中位下降5分(P=0.037)。作者建议每6个月需重复门诊治疗者宜考虑更早手术干预。

要点

  • 连续门诊KTP或PDL激光治疗声带白斑可控制疾病并保留嗓音,并发症少。
  • 失败者治疗间隔中位2.3个月,显著短于应答者的8.9个月(P=0.038)。
  • 失败者疾病消退中位49.3%,显著低于应答者的100%(P=0.006)。

核心结论

  • 连续门诊KTP或PDL激光治疗声带白斑对疾病控制有效、并发症少并保留嗓音质量。
  • 作者建议每6个月需重复门诊治疗的患者可能从更早的手术干预中获益。
  • 与门诊治疗成功相关的其他因素仍不明确。

研究设计与样本

  • 回顾性分析2008—2015年46例接受门诊KTP或PDL激光治疗的声带白斑患者。
  • 末次激光治疗后中位随访19.6个月。
  • 主要结局为疾病控制率和ImageJ分析的疾病消退百分比,次要结局为VHI-10嗓音评估。

主要发现

  • 患者接受门诊激光治疗中位2次(范围1—6次),治疗间隔中位7.6个月。
  • 末次治疗后19例(41.3%)无病变,2例(4.3%)进展为浸润癌,总体疾病消退中位77.1%(P<0.001)。
  • VHI-10评分中位下降5分(P=0.037)。
  • 31例(67.4%)为应答者,13例(28.3%)需手术干预,2例(4%)接受放疗。
  • 与应答者相比,失败者治疗间隔更短(中位2.3个月 vs 8.9个月,P=0.038),疾病消退更少(中位49.3% vs 100%,P=0.006)。

临床怎么用

  • 作者建议每6个月需重复门诊激光治疗的患者可能从更早的手术干预中获益。
  • 与门诊治疗成功相关的其他因素原文未明确。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Although vocal fold (VF) leukoplakia is commonly treated with in-office laser, there is no data on its long-term effectiveness. This study hypothesizes that VF leukoplakia treated by serial in-office laser results in long-term disease control with maintenance of voice and minimal morbidity. STUDY DESIGN: Retrospective review (2008-2015). METHODS: Forty-six patients with VF leukoplakia treated by in-office KTP (potassium titanyl phosphate) or PDL (pulsed dye laser) were included. Median follow-up from final laser treatment was 19.6 months. Main outcomes included: 1) rate of disease control, 2) percentage of disease regression using ImageJ analysis. Secondary outcomes included vocal assessment using the Voice Handicap Index-10 (VHI-10). RESULTS: Patients underwent a median of 2 (range: 1-6) in-office laser treatments. Time between treatments was median 7.6 months. After final treatment, 19 patients (41.3%) had no disease; two patients (4.3%) progressed to invasive cancer; overall disease regression was median 77.1% (P < 0.001); and VHI-10 score decreased by median 5 (P = 0.037). Thirty-one patients (67.4%) were responders (controlled with in-office treatment only); failures were 13 patients (28.3%) who required operative intervention and two patients (4%) who underwent radiation. Compared to responders, failures demonstrated significantly shorter duration between treatments (median 2.3 vs. 8.9 months, P = 0.038) and significantly less regression (median 49.3% vs. 100%, P = 0.006). CONCLUSION: Serial outpatient KTP or PDL treatment of VF leukoplakia is effective for disease control with minimal morbidity and preservation of voice quality. We suggest that patients requiring repeated in-office treatment every 6 months may benefit from earlier operative intervention; other factors associated with in-office success remain unclear. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:1644-1651, 2017.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Koss SL, Baxter P, Panossian H, et al. Serial in-office laser treatment of vocal fold leukoplakia: Disease control and voice outcomes. Laryngoscope. 2017. PMID: 28083976. doi:10.1002/lary.26445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。